Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

UroGen Pharma (URGN) Treasury Shares: 2016-2024

  • UroGen Pharma's Treasury Shares rose 37.24% to $1.5 million in Q4 2024 from the same period last year, while for Dec 2024 it was $1.5 million, marking a year-over-year increase of 37.24%. This contributed to the annual value of $1.5 million for FY2024, which is 37.24% up from last year.
  • Latest data reveals that UroGen Pharma reported Treasury Shares of $1.5 million as of Q4 2024, which was up 37.24% from $1.1 million recorded in Q4 2023.
  • Over the past 5 years, UroGen Pharma's Treasury Shares peaked at $1.5 million during Q4 2024, and registered a low of $690,955 during Q4 2022.
  • Its 3-year average for Treasury Shares is $1.1 million, with a median of $1.1 million in 2023.
  • Its Treasury Shares has fluctuated over the past 5 years, first decreased by 8.27% in 2022, then surged by 59.01% in 2023.
  • Quarterly analysis of 5 years shows UroGen Pharma's Treasury Shares stood at $720,416 in 2020, then rose by 4.56% to $753,274 in 2021, then decreased by 8.27% to $690,955 in 2022, then skyrocketed by 59.01% to $1.1 million in 2023, then skyrocketed by 37.24% to $1.5 million in 2024.
  • Its last three reported values are $1.5 million in Q4 2024, $1.1 million for Q4 2023, and $690,955 during Q4 2022.